GlassScriptPhysician profile
Gregory J Orloff
NPI 1750358776
$1,288.54
in general payments reported to CMS, 2019-2025
24 companies · $249 in 2025
The $249 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $208 · 2021: $11.92 · 2022: $67.01 · 2023: $189 · 2024: $418 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $332.32 | 2019-2024 | Talvey, Darzalex, Tecvayli |
| Celgene Corporation | $132.41 | 2020-2025 | Reblozyl |
| Daiichi Sankyo INC. | $127.31 | 2023-2025 | Injectafer, Enhertu |
| Incyte Corporation | $65.50 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Novartis Pharmaceuticals Corporation | $63.81 | 2024 | |
| Amgen INC. | $60.41 | 2020-2023 | Kyprolis, Lumakras |
| Ipsen Biopharmaceuticals, INC | $48.90 | 2019-2025 | Onivyde |
| Bioprotect Medical, INC. | $45.51 | 2024 | Bioprotect Balloon Implant System |
| E.R. Squibb & Sons, L.L.C. | $38.63 | 2022-2024 | Opdivo |
| Pfizer INC. | $38.19 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.86 | 2025 | Fruzaqla |
| Iovance Biotherapeutics, INC. | $35.53 | 2025 | Amtagvi |
| Pharmacyclics LLC, An Abbvie Company | $34.56 | 2023 | Epkinly, Imbruvica |
| Merck Sharp & Dohme LLC | $33.69 | 2023-2024 | Keytruda, Lynparza |
| Tersera Therapeutics LLC | $33.12 | 2025 | Zoladex |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $28.70 | 2019 | |
| Genzyme Corporation | $28.62 | 2022 | |
| Servier Pharmaceuticals LLC | $23.44 | 2024 | |
| Adc Therapeutics America, INC. | $17.91 | 2024 | |
| Abbvie INC. | $17.88 | 2024 | |
| Mirati Therapeutics, INC. | $17.04 | 2023 | Krazati |
| Eisai INC. | $16.28 | 2023 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Orloff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.